Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)
With sales worth US$ 57 Million in 2010, biosimilars are still far from their billion dollar sales potential that most analysts believe they will generate. This market, however, unlike small molecule generics, is expected to be more akin to a marathon than a sprint. IMARC Group, one of the world’s leading research and advisory firms, in its new report “Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)” finds that biosimilars in the US will soon represent a multi-billion dollar market as they would be posing stiff competition to as many as twenty biological molecules during 2011-2020.
Findings from the report suggest that the historical performance of Omnitrope cannot be taken as a benchmark to gauge the potential of pipeline biosimilars as market acceptance for each biosimilar class is expected to vary significantly from one another. The report expects that the competition between branded biological drugs and their biosimilar counterparts would be more of a brand-brand competition than a brand-generic competition. The high costs involved in the development and launch of biosimilars are expected to limit the number of players in this market. As a result, erosions in price and volume caused by biosimilars are likely to be lower compared to those created by small molecule generics.
IMARC’s new report entitled “Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)” provides an analytical and statistical insight into the US biosimilar market. The study, that has been undertaken using desk-based as well as qualitative primary research, provides and draws upon analysis of six aspects of the US biosimilar market.
Key Aspects Analyzed:
Evaluating the Current Market Landscape of Biosimilars:
Evaluating the Extent of Price, Sales and Volume Erosions Caused by Biosimilars:
Evaluating the Market Potential of Biosimilars Across Various Molecules:
Molecules Covered: Somatropin (Genotropin/Humatrope/Other HGH), Epoetin Alfa (Epogen/Eprex), Filgrastim (Neupogen), Pegfilgrastim (Neulasta), Insulin Lispro (Humalog), Insulin Glargine (Lantus), Insulin Detemir (Levemir), Interferon Beta-1A (Avonex), Interferon Beta-1A (Rebif), Interferon Beta-1B (Betaferon), Bevacizumab (Avastin), Trastuzumab (Herceptin), Rituximab (Mabthera/Rituxan), Cetuximab (Erbitux), Etanercept (Enbrel), Infliximab (Remicade), Adalimumab (Humira), Ranibizumab (Lucentis), Omalizumab (Xolair) and Natalizumab (Tysabri).
Focus of the Analysis for Each Molecule:
Evaluating the Sales of Biosimilars across Various Indications:
Indications Covered: Immunology & Inflammation, Diabetes, Oncology, Blood Disorders and Growth Deficiency
Focus of the Analysis for Each Indication:
Evaluating the Biosimilar Competitive Landscape:
Understanding the Current Legislation on Biosimilars:
Findings from the report suggest that the historical performance of Omnitrope cannot be taken as a benchmark to gauge the potential of pipeline biosimilars as market acceptance for each biosimilar class is expected to vary significantly from one another. The report expects that the competition between branded biological drugs and their biosimilar counterparts would be more of a brand-brand competition than a brand-generic competition. The high costs involved in the development and launch of biosimilars are expected to limit the number of players in this market. As a result, erosions in price and volume caused by biosimilars are likely to be lower compared to those created by small molecule generics.
IMARC’s new report entitled “Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)” provides an analytical and statistical insight into the US biosimilar market. The study, that has been undertaken using desk-based as well as qualitative primary research, provides and draws upon analysis of six aspects of the US biosimilar market.
Key Aspects Analyzed:
Evaluating the Current Market Landscape of Biosimilars:
- Identification of currently marketed biosimilars and their historical performance
- Identifying the reasons for the slow uptake of currently marketed biosimilars
- Analyzing historical data to formulate conclusions on the future growth and market trends of biosimilars
Evaluating the Extent of Price, Sales and Volume Erosions Caused by Biosimilars:
- Analyzing historical time series data on price, volume and sales erosion in the US & Europe
- Analyzing previous models and assumptions on price and volume erosion caused by biosimilars
- Evaluating and comparing price and volume erosion created by biosimilars vis-a-vis by small molecule generics
- Evaluating and comparing price, volume and sales erosion by biosimilars across various biological classes
Evaluating the Market Potential of Biosimilars Across Various Molecules:
Molecules Covered: Somatropin (Genotropin/Humatrope/Other HGH), Epoetin Alfa (Epogen/Eprex), Filgrastim (Neupogen), Pegfilgrastim (Neulasta), Insulin Lispro (Humalog), Insulin Glargine (Lantus), Insulin Detemir (Levemir), Interferon Beta-1A (Avonex), Interferon Beta-1A (Rebif), Interferon Beta-1B (Betaferon), Bevacizumab (Avastin), Trastuzumab (Herceptin), Rituximab (Mabthera/Rituxan), Cetuximab (Erbitux), Etanercept (Enbrel), Infliximab (Remicade), Adalimumab (Humira), Ranibizumab (Lucentis), Omalizumab (Xolair) and Natalizumab (Tysabri).
Focus of the Analysis for Each Molecule:
- Historical background and overview
- Historical brand sales
- Patent position
- Competing products
- Biosimilars in pipeline
- Brand and biosimilar sales forecasts
Evaluating the Sales of Biosimilars across Various Indications:
Indications Covered: Immunology & Inflammation, Diabetes, Oncology, Blood Disorders and Growth Deficiency
Focus of the Analysis for Each Indication:
- Historical brand sales
- Brand and biosimilar sales forecasts
- Indication wise breakup of molecules
Evaluating the Biosimilar Competitive Landscape:
- Identifying branded biological manufacturers that expect the highest amount of erosion from biosimilars
- Identifying biosimilar manufacturers and their pipelines
Understanding the Current Legislation on Biosimilars:
- An insight into the Biologics Price Competition and Innovation Act
- An insight into the key biosimilar issues that still remain unaddressed
- Interchangeability and Substitutability
- Data Exclusivity
- Statutory provisions for dealing with patent litigations
1 MARKET DEFINITIONS & RESEARCH METHODOLOGY
2 EXECUTIVE SUMMARY
3 THE US BIOSIMILAR MARKET LANDSCAPE
4 US BIOSIMILAR MARKET: CURRENT EXPERIENCE
4.1 The Performance of Growth Hormone Biosimilars Has Been Dismal So Far
4.2 Pediatrics Represent the Prime Customer Base for Growth Hormones
4.3 Omnitrope Was Launched with an Inconvenient Delivery Device
4.4 Prescribing Patterns for Omnitrope
4.5 Uptake is Likely to Increase with the Accumulation of Post-Market Safety Data
5 US BIOSIMLAR MARKET: HOW MUCH PRICE, VOLUME & SALES EROSION WILL RESULT
5.1 Omnitrope Cannot be Taken as a Benchmark to Gauge the Performance of Other Biosimilars
5.2 The European Uptake of ESA & GCSF Biosimilars Give Us a Very Positive Outlook for the US
5.3 Models for Biosimilar Volume Erosion Across Various Biological Classes
5.4 Models for Biosimilar Price Erosion Across Various Biological Classes
5.5 Models for Biosimilar Sales Erosion Across Various Biological Classes
6 US BIOSIMILAR MARKET: CURRENT TRENDS & FORECAST BY DRUG
6.1 Growth Hormones
6.1.1 Somatropin (Genotropin/Humatrope/Other HGH)
6.1.1.1 Drug Overview
6.1.1.2 Current Brand & Biosimilar Sales
6.1.1.3 Brand & Biosimilar Forecast (2011-2020)
6.2 Erythropoiesis Stimulating Agents
6.2.1 Epoetin Alfa (Epogen/Eprex)
6.2.1.1 Drug Overview
6.2.1.2 Historical Brand Sales
6.2.1.3 Brand & Biosimilar Forecast (2011-2020)
6.3 Granulocyte Colony Stimulating Factor
6.3.1 Filgrastim (Neupogen)
6.3.1.1 Drug Overview
6.3.1.2 Historical Brand Sales
6.3.1.3 Brand & Biosimilar Forecast (2011-2020)
6.3.2 Pegfilgrastim (Neulasta)
6.3.2.1 Drug Overview
6.3.2.2 Historical Brand Sales
6.3.2.3 Brand & Biosimilar Forecast (2011-2020)
6.4 Insulin
6.4.1 Insulin Lispro (Humalog)
6.4.1.1 Drug Overview
6.4.1.2 Historical Brand Sales
6.4.1.3 Brand & Biosimilar Forecast (2011-2020)
6.4.2 Insulin Glargine (Lantus)
6.4.2.1 Drug Overview
6.4.2.2 Historical Brand Sales
6.4.2.3 Brand & Biosimilar Forecast (2011-2020)
6.4.3 Insulin Detemir (Levemir)
6.4.3.1 Drug Overview
6.4.3.2 Historical Brand Sales
6.4.3.3 Brand & Biosimilar Forecast (2011-2020)
6.5 Interferons
6.5.1 Interferon Beta-1A (Avonex)
6.5.1.1 Drug Overview
6.5.1.2 Historical Brand Sales
6.5.1.3 Brand & Biosimilar Forecast (2011-2020)
6.5.2 Interferon Beta-1A (Rebif)
6.5.2.1 Drug Overview
6.5.2.2 Historical Biosimilar Sales
6.5.2.3 Brand & Biosimilar Forecast (2011-2020)
6.5.3 Interferon Beta-1B (Betaferon/Betaseron)
6.5.3.1 Drug Overview
6.5.3.2 Historical Brand Sales
6.5.3.3 Brand & Biosimilar Forecast (2011-2020)
6.6 TNF Alpha & Monoclonal Antibodies (Immunology & Inflammation)
6.6.1 Etanercept (Enbrel)
6.6.1.1 Drug Overview
6.6.1.2 Historical Brand Sales
6.6.1.3 Brand & Biosimilar Forecast (2011-2020)
6.6.2 Infliximab (Remicade)
6.6.2.1 Drug Overview
6.6.2.2 Historical Brand Sales
6.6.2.3 Brand & Biosimilar Forecast (2011-2020)
6.6.3 Adalimumab (Humira)
6.6.3.1 Drug Overview
6.6.3.2 Historical Brand Sales
6.6.3.3 Brand & Biosimilar Forecast (2011-2020)
6.6.4 Ranibizumab (Lucentis)
6.6.4.1 Drug Overview
6.6.4.2 Historical Brand Sales
6.6.4.3 Brand & Biosimilar Forecast (2011-2020)
6.6.5 Omalizumab (Xolair)
6.6.5.1 Drug Overview
6.6.5.2 Historical Brand Sales
6.6.5.3 Brand & Biosimilar Forecast (2011-2020)
6.6.6 Natalizumab (Tysabri)
6.6.6.1 Drug Overview
6.6.6.2 Historical Brand Sales
6.6.6.3 Brand & Biosimilar Forecast (2011-2020)
6.7 Monoclonal Antibodies (Oncology)
6.7.1 Bevacizumab (Avastin)
6.7.1.1 Drug Overview
6.7.1.2 Historical Brand Sales
6.7.1.3 Brand & Biosimilar Forecast (2011-2020)
6.7.2 Trastuzumab (Herceptin)
6.7.2.1 Drug Overview
6.7.2.2 Historical Biosimilar Sales
6.7.2.3 Brand & Biosimilar Forecast (2011-2020)
6.7.3 Rituximab (Mabthera)
6.7.3.1 Drug Overview
6.7.3.2 Historical Biosimilar Sales
6.7.3.3 Brand & Biosimilar Forecast (2011-2020)
6.7.4 Cetuximab (Erbitux)
6.7.4.1 Drug Overview
6.7.4.2 Historical Brand Sales
6.7.4.3 Brand & Biosimilar Forecast (2011-2020)
7 US BIOSIMILAR MARKET: CURRENT TRENDS & FORECAST BY INDICATION
7.1 Immunology & Inflammation
7.1.1 Current Trends & Forecast
7.1.2 Biosimilar Sales Breakup by Molecule
7.2 Diabetes
7.2.1 Current Trends & Forecast
7.2.2 Biosimilar Sales Breakup by Molecule
7.3 Oncology
7.3.1 Current Trends & Forecast
7.3.2 Biosimilar Sales Breakup by Molecule
7.4 Blood Disorders
7.4.1 Current Trends & Forecast
7.4.2 Biosimilar Sales Breakup by Molecule
7.5 Growth Deficiency
7.5.1 Current Trends & Forecast
7.5.2 Biosimilar Sales Breakup by Molecule
8 COMPETITIVE LANDSCAPE
8.1 Branded Manufacturers: Companies Facing the Highest Amount of Biosimilar Erosion
8.2 Biosimilar Manufacturers: Companies Gaining the Most From Biosimilar Launches
9 BIOSIMILAR LEGISLATION IN THE US
9.1 The Biologics Price Competition and Innovation Act: An Insight
9.2 Biosimilar Issues that Still Remain Unaddressed
9.3 Major Issues Impacting the Business Strategies of Biological Companies
9.3.1 Interchangeability & Substitutability
9.3.2 Data Exclusivity
9.3.3 Patent Litigation
10 KEY COMPANY PROFILES
10.1 Teva Pharmaceutical Industries Ltd.
10.2 Sandoz, Inc.
10.3 Hospira, Inc.
10.4 STADA Arzneimittel AG
10.5 Dr. Reddy's Laboratories Ltd.
10.6 Celltrion, Inc.
10.7 Bioexpress Therapeutics SA
2 EXECUTIVE SUMMARY
3 THE US BIOSIMILAR MARKET LANDSCAPE
4 US BIOSIMILAR MARKET: CURRENT EXPERIENCE
4.1 The Performance of Growth Hormone Biosimilars Has Been Dismal So Far
4.2 Pediatrics Represent the Prime Customer Base for Growth Hormones
4.3 Omnitrope Was Launched with an Inconvenient Delivery Device
4.4 Prescribing Patterns for Omnitrope
4.5 Uptake is Likely to Increase with the Accumulation of Post-Market Safety Data
5 US BIOSIMLAR MARKET: HOW MUCH PRICE, VOLUME & SALES EROSION WILL RESULT
5.1 Omnitrope Cannot be Taken as a Benchmark to Gauge the Performance of Other Biosimilars
5.2 The European Uptake of ESA & GCSF Biosimilars Give Us a Very Positive Outlook for the US
5.3 Models for Biosimilar Volume Erosion Across Various Biological Classes
5.4 Models for Biosimilar Price Erosion Across Various Biological Classes
5.5 Models for Biosimilar Sales Erosion Across Various Biological Classes
6 US BIOSIMILAR MARKET: CURRENT TRENDS & FORECAST BY DRUG
6.1 Growth Hormones
6.1.1 Somatropin (Genotropin/Humatrope/Other HGH)
6.1.1.1 Drug Overview
6.1.1.2 Current Brand & Biosimilar Sales
6.1.1.3 Brand & Biosimilar Forecast (2011-2020)
6.2 Erythropoiesis Stimulating Agents
6.2.1 Epoetin Alfa (Epogen/Eprex)
6.2.1.1 Drug Overview
6.2.1.2 Historical Brand Sales
6.2.1.3 Brand & Biosimilar Forecast (2011-2020)
6.3 Granulocyte Colony Stimulating Factor
6.3.1 Filgrastim (Neupogen)
6.3.1.1 Drug Overview
6.3.1.2 Historical Brand Sales
6.3.1.3 Brand & Biosimilar Forecast (2011-2020)
6.3.2 Pegfilgrastim (Neulasta)
6.3.2.1 Drug Overview
6.3.2.2 Historical Brand Sales
6.3.2.3 Brand & Biosimilar Forecast (2011-2020)
6.4 Insulin
6.4.1 Insulin Lispro (Humalog)
6.4.1.1 Drug Overview
6.4.1.2 Historical Brand Sales
6.4.1.3 Brand & Biosimilar Forecast (2011-2020)
6.4.2 Insulin Glargine (Lantus)
6.4.2.1 Drug Overview
6.4.2.2 Historical Brand Sales
6.4.2.3 Brand & Biosimilar Forecast (2011-2020)
6.4.3 Insulin Detemir (Levemir)
6.4.3.1 Drug Overview
6.4.3.2 Historical Brand Sales
6.4.3.3 Brand & Biosimilar Forecast (2011-2020)
6.5 Interferons
6.5.1 Interferon Beta-1A (Avonex)
6.5.1.1 Drug Overview
6.5.1.2 Historical Brand Sales
6.5.1.3 Brand & Biosimilar Forecast (2011-2020)
6.5.2 Interferon Beta-1A (Rebif)
6.5.2.1 Drug Overview
6.5.2.2 Historical Biosimilar Sales
6.5.2.3 Brand & Biosimilar Forecast (2011-2020)
6.5.3 Interferon Beta-1B (Betaferon/Betaseron)
6.5.3.1 Drug Overview
6.5.3.2 Historical Brand Sales
6.5.3.3 Brand & Biosimilar Forecast (2011-2020)
6.6 TNF Alpha & Monoclonal Antibodies (Immunology & Inflammation)
6.6.1 Etanercept (Enbrel)
6.6.1.1 Drug Overview
6.6.1.2 Historical Brand Sales
6.6.1.3 Brand & Biosimilar Forecast (2011-2020)
6.6.2 Infliximab (Remicade)
6.6.2.1 Drug Overview
6.6.2.2 Historical Brand Sales
6.6.2.3 Brand & Biosimilar Forecast (2011-2020)
6.6.3 Adalimumab (Humira)
6.6.3.1 Drug Overview
6.6.3.2 Historical Brand Sales
6.6.3.3 Brand & Biosimilar Forecast (2011-2020)
6.6.4 Ranibizumab (Lucentis)
6.6.4.1 Drug Overview
6.6.4.2 Historical Brand Sales
6.6.4.3 Brand & Biosimilar Forecast (2011-2020)
6.6.5 Omalizumab (Xolair)
6.6.5.1 Drug Overview
6.6.5.2 Historical Brand Sales
6.6.5.3 Brand & Biosimilar Forecast (2011-2020)
6.6.6 Natalizumab (Tysabri)
6.6.6.1 Drug Overview
6.6.6.2 Historical Brand Sales
6.6.6.3 Brand & Biosimilar Forecast (2011-2020)
6.7 Monoclonal Antibodies (Oncology)
6.7.1 Bevacizumab (Avastin)
6.7.1.1 Drug Overview
6.7.1.2 Historical Brand Sales
6.7.1.3 Brand & Biosimilar Forecast (2011-2020)
6.7.2 Trastuzumab (Herceptin)
6.7.2.1 Drug Overview
6.7.2.2 Historical Biosimilar Sales
6.7.2.3 Brand & Biosimilar Forecast (2011-2020)
6.7.3 Rituximab (Mabthera)
6.7.3.1 Drug Overview
6.7.3.2 Historical Biosimilar Sales
6.7.3.3 Brand & Biosimilar Forecast (2011-2020)
6.7.4 Cetuximab (Erbitux)
6.7.4.1 Drug Overview
6.7.4.2 Historical Brand Sales
6.7.4.3 Brand & Biosimilar Forecast (2011-2020)
7 US BIOSIMILAR MARKET: CURRENT TRENDS & FORECAST BY INDICATION
7.1 Immunology & Inflammation
7.1.1 Current Trends & Forecast
7.1.2 Biosimilar Sales Breakup by Molecule
7.2 Diabetes
7.2.1 Current Trends & Forecast
7.2.2 Biosimilar Sales Breakup by Molecule
7.3 Oncology
7.3.1 Current Trends & Forecast
7.3.2 Biosimilar Sales Breakup by Molecule
7.4 Blood Disorders
7.4.1 Current Trends & Forecast
7.4.2 Biosimilar Sales Breakup by Molecule
7.5 Growth Deficiency
7.5.1 Current Trends & Forecast
7.5.2 Biosimilar Sales Breakup by Molecule
8 COMPETITIVE LANDSCAPE
8.1 Branded Manufacturers: Companies Facing the Highest Amount of Biosimilar Erosion
8.2 Biosimilar Manufacturers: Companies Gaining the Most From Biosimilar Launches
9 BIOSIMILAR LEGISLATION IN THE US
9.1 The Biologics Price Competition and Innovation Act: An Insight
9.2 Biosimilar Issues that Still Remain Unaddressed
9.3 Major Issues Impacting the Business Strategies of Biological Companies
9.3.1 Interchangeability & Substitutability
9.3.2 Data Exclusivity
9.3.3 Patent Litigation
10 KEY COMPANY PROFILES
10.1 Teva Pharmaceutical Industries Ltd.
10.2 Sandoz, Inc.
10.3 Hospira, Inc.
10.4 STADA Arzneimittel AG
10.5 Dr. Reddy's Laboratories Ltd.
10.6 Celltrion, Inc.
10.7 Bioexpress Therapeutics SA
LIST OF FIGURES
Figure 1 1: Model Used to Forecast Brand and Biosimilar Sales
Figure 2 1: US: Executive Summary: Biosimilar Timeline: 2011-2020
Figure 3 1: US: Biosimilar Market (in Million US$), 2007-2010
Figure 3 2: US: Biosimilar Timeline: 2011-2020
Figure 3 3: US: Biosimilar Market Forecast (in Million US$), 2011-2020
Figure 4 1: US: Human Growth Hormone Market: Sales Share of Different Brands & Biosimilars (in %), 2007-2010
Figure 4 2: US: Human Growth Hormone Market: Brand & Biosimilar Patient Share (in %), 2007-2020
Figure 5 1: US, Germany, France, Italy, Spain & UK: Somatropin Biosimilars: Patient Share (in %), 2007-2010
Figure 5 2: Germany, France, Italy, Spain & UK: Epoetin Alfa Biosimilars: Patient Share (in %), 2007-2010
Figure 5 3: US: Percentage of Physicians Expected to Prescribe ESA Biosimilars After They Have Been Launched, (in %), 2010
Figure 5 4: Germany, France, Italy, Spain & UK: Filgrastim Biosimilars: Patient Share (in %), 2008-2010
Figure 5 5: Average Generic Volume Erosion of Molecules Based-on Complex Drug Characteristics, (in %)
Figure 5 6: Average Generic Volume Erosion Across Various Countries From Time Since First Generic Entry, (in %)
Figure 5 7: Average Generic Price Erosion of Molecules Based Upon Complex Drug Characteristics, (in %)
Figure 5 8: Average Generic Price Erosion Across Various Countries From Time Since First Generic Entry
Figure 5 9: Average Brand Price Erosion Across Various Countries From Time Since First Generic Entry
Figure 6 1: US: Somatropin (Genotropin/Humatrope/Other HGH) Market: Brand & Biosimilar Sales Share (in %), 2007-2010
Figure 6 2: US: Somatropin (Genotropin/Humatrope/Other HGH) Market: Share of Marketed Brands & Biosimilars (in %), 2007-2010
Figure 6 3: US: Somatropin (Genotropin/Humatrope/Other HGH) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 4: US: Epoetin Alfa (Epogen/Eprex) Market: Share of Marketed Brands (in %), 2007-2010
Figure 6 5: US: Epoetin Alfa (Epogen/Eprex) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 6: US: Filgrastim (Neupogen) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 7: US: Pegfilgrastim (Neulasta) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 8: US: Insulin Lispro (Humalog) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 9: US: Insulin Glargine (Lantus) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 10: US: Insulin Detemir (Levemir) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 11: US: Interferon Beta-1A (Avonex) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 12: US: Interferon Beta-1A (Rebif) Market: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 13: US: Interferon Beta-1B (Betaferon/Betaseron) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 14: US: Etanercept (Enbrel) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 15: US: Infliximab (Remicade) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 16: US: Adalimumab (Humira) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 17: US: Ranibizumab (Lucentis) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 18 : US: Omalizumab (Xolair) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 19: US: Natalizumab (Tysabri) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 20: US: Bevacizumab (Avastin) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 21: US: Trastuzumab (Herceptin) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 22 : US: Rituximab (Mabthera) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 23: US: Cetuximab (Erbitux) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 7 1: US: Biosimilar Market Forecast: Share by Indication (in %), 2011-2020
Figure 7 2: US: Immunology & Inflammation Market Forecast: Brand & Biosimilar Share (in %), 2011-2020
Figure 7 3: US: Immunology & Inflammation Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020
Figure 7 4: US: Diabetes Market forecast: Brand & Biosimilar Share (in %), 2011-2020
Figure 7 5: US: Diabetes Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020
Figure 7 6: US: Oncology Market Forecast: Brand & Biosimilar Share (in %), 2011-2020
Figure 7 7: US: Oncology Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020
Figure 7 8: US: Blood Disorder Market Forecast: Brand & Biosimilar Share (in %), 2011-2020
Figure 7 9: US: Blood Disorder Biosimilar Market Forecast: Anemia & Neutropenia Sales (in %), 2011-2020
Figure 7 10: US: Blood Disorder Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020
Figure 7 11: US: Growth Deficiency Market: Brand & Biosimilar Share (in %), 2007-2010
Figure 7 12: US: Growth Deficiency Market Forecast: Brand & Biosimilar Share (in %), 2011-2020
Figure 8 1: US: Innovator Company Brand Sales That Face Biosimilar Sales Erosion (in Million US$), 2010 & 2020
Figure 1 1: Model Used to Forecast Brand and Biosimilar Sales
Figure 2 1: US: Executive Summary: Biosimilar Timeline: 2011-2020
Figure 3 1: US: Biosimilar Market (in Million US$), 2007-2010
Figure 3 2: US: Biosimilar Timeline: 2011-2020
Figure 3 3: US: Biosimilar Market Forecast (in Million US$), 2011-2020
Figure 4 1: US: Human Growth Hormone Market: Sales Share of Different Brands & Biosimilars (in %), 2007-2010
Figure 4 2: US: Human Growth Hormone Market: Brand & Biosimilar Patient Share (in %), 2007-2020
Figure 5 1: US, Germany, France, Italy, Spain & UK: Somatropin Biosimilars: Patient Share (in %), 2007-2010
Figure 5 2: Germany, France, Italy, Spain & UK: Epoetin Alfa Biosimilars: Patient Share (in %), 2007-2010
Figure 5 3: US: Percentage of Physicians Expected to Prescribe ESA Biosimilars After They Have Been Launched, (in %), 2010
Figure 5 4: Germany, France, Italy, Spain & UK: Filgrastim Biosimilars: Patient Share (in %), 2008-2010
Figure 5 5: Average Generic Volume Erosion of Molecules Based-on Complex Drug Characteristics, (in %)
Figure 5 6: Average Generic Volume Erosion Across Various Countries From Time Since First Generic Entry, (in %)
Figure 5 7: Average Generic Price Erosion of Molecules Based Upon Complex Drug Characteristics, (in %)
Figure 5 8: Average Generic Price Erosion Across Various Countries From Time Since First Generic Entry
Figure 5 9: Average Brand Price Erosion Across Various Countries From Time Since First Generic Entry
Figure 6 1: US: Somatropin (Genotropin/Humatrope/Other HGH) Market: Brand & Biosimilar Sales Share (in %), 2007-2010
Figure 6 2: US: Somatropin (Genotropin/Humatrope/Other HGH) Market: Share of Marketed Brands & Biosimilars (in %), 2007-2010
Figure 6 3: US: Somatropin (Genotropin/Humatrope/Other HGH) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 4: US: Epoetin Alfa (Epogen/Eprex) Market: Share of Marketed Brands (in %), 2007-2010
Figure 6 5: US: Epoetin Alfa (Epogen/Eprex) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 6: US: Filgrastim (Neupogen) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 7: US: Pegfilgrastim (Neulasta) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 8: US: Insulin Lispro (Humalog) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 9: US: Insulin Glargine (Lantus) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 10: US: Insulin Detemir (Levemir) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 11: US: Interferon Beta-1A (Avonex) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 12: US: Interferon Beta-1A (Rebif) Market: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 13: US: Interferon Beta-1B (Betaferon/Betaseron) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 14: US: Etanercept (Enbrel) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 15: US: Infliximab (Remicade) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 16: US: Adalimumab (Humira) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 17: US: Ranibizumab (Lucentis) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 18 : US: Omalizumab (Xolair) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 19: US: Natalizumab (Tysabri) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 20: US: Bevacizumab (Avastin) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 21: US: Trastuzumab (Herceptin) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 22 : US: Rituximab (Mabthera) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 6 23: US: Cetuximab (Erbitux) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020
Figure 7 1: US: Biosimilar Market Forecast: Share by Indication (in %), 2011-2020
Figure 7 2: US: Immunology & Inflammation Market Forecast: Brand & Biosimilar Share (in %), 2011-2020
Figure 7 3: US: Immunology & Inflammation Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020
Figure 7 4: US: Diabetes Market forecast: Brand & Biosimilar Share (in %), 2011-2020
Figure 7 5: US: Diabetes Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020
Figure 7 6: US: Oncology Market Forecast: Brand & Biosimilar Share (in %), 2011-2020
Figure 7 7: US: Oncology Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020
Figure 7 8: US: Blood Disorder Market Forecast: Brand & Biosimilar Share (in %), 2011-2020
Figure 7 9: US: Blood Disorder Biosimilar Market Forecast: Anemia & Neutropenia Sales (in %), 2011-2020
Figure 7 10: US: Blood Disorder Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020
Figure 7 11: US: Growth Deficiency Market: Brand & Biosimilar Share (in %), 2007-2010
Figure 7 12: US: Growth Deficiency Market Forecast: Brand & Biosimilar Share (in %), 2011-2020
Figure 8 1: US: Innovator Company Brand Sales That Face Biosimilar Sales Erosion (in Million US$), 2010 & 2020
LIST OF TABLES
Table 1 1: US Biosimilar/Follow-On Biologics Market: Market Definition & Overview
Table 2 1: US: Executive Summary: Major Biosimilar Launches
Table 2 2: US: Executive Summary: Biosimilar Sales Forecast by Molecule (in Million US$), 2011-2020
Table 2 3: US: Executive Summary: Biosimilar Sales Forecast by Indication (in Million US$), 2011-2020
Table 3 1: US: Patent Expiries and Biosimilar Launch
Table 5 1: Biosimilar Vulnerability of Various Biopharmaceutical Classes
Table 5 2: Germany, France, Italy, Spain & UK: Epoetin Alfa Biosimilars: Patient Share (in %), 2007-2010
Table 5 3: Germany, France, Italy, Spain & UK: Filgrastim Biosimilars: Patient Share (in %), 2008-2010
Table 5 4: US: Various Studies & Assumptions for Biosimilar Volume Erosion
Table 5 5: US, Germany and UK: Biosimilar Volume Penetration by Molecule After 3 years from Launch (in %)
Table 5 6: Various Studies & Assumptions for Biosimilar Price Erosion
Table 5 7: US, Germany and UK: Biosimilar Sales Penetration by Molecule After 3 years from Launch (in %)
Table 6 1: US: Biosimilar Sales by Molecule (in Million US$), 2007-2010
Table 6 2: US: Biosimilar Sales Forecast by Molecule (in Million US$), 2011-2020
Table 6 3: US: Biosimilar Share Forecast by Molecule (in %), 2011-2020
Table 6 4: US: Somatropin: Brand & Biosimilar Market Overview
Table 6 5: US: Somatropin (Genotropin/Humatrope/Other HGH) Market: Brand & Biosimilar Sales/Patient Share, 2007-2010
Table 6 6: US: Somatropin (Genotropin/Humatrope/Other HGH) Market: Sales of Marketed Brands & Biosimilars (in Million US$), 2007-2010
Table 6 7: US: Somatropin (Genotropin/Humatrope/Other HGH) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 8: US: Epoetin Alfa: Brand & Biosimilar Market Overview
Table 6 9: US: Epoetin Alfa (Epogen/Eprex) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 10: US: Epoetin Alfa (Epogen/Eprex) Market: Sales of Marketed Brands (in Million US$), 2007-2010
Table 6 11: US: Epoetin Alfa (Epogen/Eprex) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 12: US: Filgrastim: Brand & Biosimilar Market Overview
Table 6 13: US: Filgrastim (Neupogen) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 14: US: Filgrastim (Neupogen) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 15: US: Pegfilgrastim: Brand & Biosimilar Market Overview
Table 6 16: US: Pegfilgrastim (Neulasta) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 17: US: Pegfilgrastim (Neulasta) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 18: US: Insulin Lispro: Brand & Biosimilar Market Overview
Table 6 19: US: Insulin Lispro (Humalog) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 20: US: Insulin Lispro (Humalog) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 21: US: Insulin Glargine: Brand & Biosimilar Market Overview
Table 6 22: US: Insulin Glargine (Lantus) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 23: US: Insulin Glargine (Lantus) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 24: US: Insulin Detemir: Brand & Biosimilar Market Overview
Table 6 25: US: Insulin Detemir (Levemir) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 26: US: Insulin Detemir (Levemir) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 27: US: Interferon Beta-1A (Avonex): Brand & Biosimilar Market Overview
Table 6 28: US: Interferon Beta-1A (Avonex) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 29: US: Interferon Beta-1A (Avonex) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 30: US: Interferon Beta-1A (Rebif): Brand & Biosimilar Market Overview
Table 6 31: US: Interferon Beta-1A (Rebif) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 32: US: Interferon Beta-1A (Rebif) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 33: US: Interferon Beta-1B: Brand & Biosimilar Market Overview
Table 6 34: US: Interferon Beta-1B (Betaferon/Betaseron) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 35: US: Interferon Beta-1B (Betaferon/Betaseron) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 36: US: Etanercept: Brand & Biosimilar Market Overview
Table 6 37: US: Etanercept (Enbrel) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 38: US: Etanercept (Enbrel) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 39: US: Infliximab: Brand & Biosimilar Market Overview
Table 6 40: US: Infliximab (Remicade) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 41: US: Infliximab (Remicade) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 42: US: Adalimumab: Brand & Biosimilar Market Overview
Table 6 43: US: Adalimumab (Humira) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 44: US: Adalimumab (Humira) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 45: US: Ranibizumab: Brand & Biosimilar Market Overview
Table 6 46: US: Ranibizumab (Lucentis) Market: Brand Sales (in Million US$), 2007-2010
Table 6 47: US: Ranibizumab (Lucentis) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 48: US: Omalizumab: Brand & Biosimilar Market Overview
Table 6 49: US: Omalizumab (Xolair) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 50: US: Omalizumab (Xolair) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 51: US: Natalizumab: Brand & Biosimilar Market Overview
Table 6 52: US: Natalizumab (Tysabri) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 53: US: Natalizumab (Tysabri) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 54: US: Bevacizumab: Brand & Biosimilar Market Overview
Table 6 55: US: Bevacizumab (Avastin) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 56: US: Bevacizumab (Avastin) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 57: US: Trastuzumab: Brand & Biosimilar Market Overview
Table 6 58: US: Trastuzumab (Herceptin) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 59: US: Trastuzumab (Herceptin) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 60: US: Rituximab: Brand & Biosimilar Market Overview
Table 6 61: US: Rituximab (Mabthera) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 62: US: Rituximab (Mabthera) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 63: US: Cetuximab: Brand & Biosimilar Market Overview
Table 6 64: US: Cetuximab (Erbitux) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 65: US: Cetuximab (Erbitux) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 7 1: US: Biosimilars Market: Indications Assigned for Various Molecules
Table 7 2: US: Biosimilars Market: Sales by Indication (in Million US$), 2007-2010
Table 7 3: US: Biosimilar Market Forecast: Sales by Indication (in Million US$), 2011-2020
Table 7 4: US: Immunology & Inflammation Market: Brand Sales (in Million US$), 2007-2010
Table 7 5: US: Immunology & Inflammation Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020
Table 7 6: US: Immunology & Inflammation Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US$), 2011-2020
Table 7 7: US: Diabetes Market: Brand Sales (in Million US$), 2007-2010
Table 7 8: US: Diabetes Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020
Table 7 9: US: Diabetes Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US$), 2011-2020
Table 7 10: US: Oncology Market: Brand Sales (in Million US$), 2007-2010
Table 7 11: US: Oncology Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020
Table 7 12: US: Oncology Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US$), 2011-2020
Table 7 13 : US: Blood Disorder Market: Brand Sales (in Million US$), 2007-2010
Table 7 14 : US: Blood Disorder Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020
Table 7 15 : US: Blood Disorder Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US$), 2011-2020
Table 7 16 : US: Growth Deficiency Market: Brand & Biosimilar Sales (in Million US$), 2007-2010
Table 7 17 : US: Growth Deficiency Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020
Table 8 1: US: Innovator Companies Facing the Highest Amount of Biosimilar Sales Erosion (in Million US$), 2010, 2013, 2016 & 2020
Table 8 2: Companies Developing Herceptin (Trastuzumab) Biosimilars
Table 8 3: Companies Developing Enbrel (Etanercept) Biosimilars
Table 8 4: Companies Developing Remicade (Infliximab) Biosimilars
Table 8 5: Companies Developing Mabthera (Rituximab) Biosimilars
Table 8 6: Companies Developing Humira (Trastuzumab) Biosimilars
Table 8 7: Companies Developing Other Biosimilars
Table 9 1: US: Overview of Biosimilar Legislations
Table 9 2: Comparison of Patent Protection and Data Exclusivity
Table 1 1: US Biosimilar/Follow-On Biologics Market: Market Definition & Overview
Table 2 1: US: Executive Summary: Major Biosimilar Launches
Table 2 2: US: Executive Summary: Biosimilar Sales Forecast by Molecule (in Million US$), 2011-2020
Table 2 3: US: Executive Summary: Biosimilar Sales Forecast by Indication (in Million US$), 2011-2020
Table 3 1: US: Patent Expiries and Biosimilar Launch
Table 5 1: Biosimilar Vulnerability of Various Biopharmaceutical Classes
Table 5 2: Germany, France, Italy, Spain & UK: Epoetin Alfa Biosimilars: Patient Share (in %), 2007-2010
Table 5 3: Germany, France, Italy, Spain & UK: Filgrastim Biosimilars: Patient Share (in %), 2008-2010
Table 5 4: US: Various Studies & Assumptions for Biosimilar Volume Erosion
Table 5 5: US, Germany and UK: Biosimilar Volume Penetration by Molecule After 3 years from Launch (in %)
Table 5 6: Various Studies & Assumptions for Biosimilar Price Erosion
Table 5 7: US, Germany and UK: Biosimilar Sales Penetration by Molecule After 3 years from Launch (in %)
Table 6 1: US: Biosimilar Sales by Molecule (in Million US$), 2007-2010
Table 6 2: US: Biosimilar Sales Forecast by Molecule (in Million US$), 2011-2020
Table 6 3: US: Biosimilar Share Forecast by Molecule (in %), 2011-2020
Table 6 4: US: Somatropin: Brand & Biosimilar Market Overview
Table 6 5: US: Somatropin (Genotropin/Humatrope/Other HGH) Market: Brand & Biosimilar Sales/Patient Share, 2007-2010
Table 6 6: US: Somatropin (Genotropin/Humatrope/Other HGH) Market: Sales of Marketed Brands & Biosimilars (in Million US$), 2007-2010
Table 6 7: US: Somatropin (Genotropin/Humatrope/Other HGH) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 8: US: Epoetin Alfa: Brand & Biosimilar Market Overview
Table 6 9: US: Epoetin Alfa (Epogen/Eprex) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 10: US: Epoetin Alfa (Epogen/Eprex) Market: Sales of Marketed Brands (in Million US$), 2007-2010
Table 6 11: US: Epoetin Alfa (Epogen/Eprex) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 12: US: Filgrastim: Brand & Biosimilar Market Overview
Table 6 13: US: Filgrastim (Neupogen) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 14: US: Filgrastim (Neupogen) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 15: US: Pegfilgrastim: Brand & Biosimilar Market Overview
Table 6 16: US: Pegfilgrastim (Neulasta) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 17: US: Pegfilgrastim (Neulasta) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 18: US: Insulin Lispro: Brand & Biosimilar Market Overview
Table 6 19: US: Insulin Lispro (Humalog) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 20: US: Insulin Lispro (Humalog) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 21: US: Insulin Glargine: Brand & Biosimilar Market Overview
Table 6 22: US: Insulin Glargine (Lantus) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 23: US: Insulin Glargine (Lantus) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 24: US: Insulin Detemir: Brand & Biosimilar Market Overview
Table 6 25: US: Insulin Detemir (Levemir) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 26: US: Insulin Detemir (Levemir) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 27: US: Interferon Beta-1A (Avonex): Brand & Biosimilar Market Overview
Table 6 28: US: Interferon Beta-1A (Avonex) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 29: US: Interferon Beta-1A (Avonex) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 30: US: Interferon Beta-1A (Rebif): Brand & Biosimilar Market Overview
Table 6 31: US: Interferon Beta-1A (Rebif) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 32: US: Interferon Beta-1A (Rebif) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 33: US: Interferon Beta-1B: Brand & Biosimilar Market Overview
Table 6 34: US: Interferon Beta-1B (Betaferon/Betaseron) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 35: US: Interferon Beta-1B (Betaferon/Betaseron) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 36: US: Etanercept: Brand & Biosimilar Market Overview
Table 6 37: US: Etanercept (Enbrel) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 38: US: Etanercept (Enbrel) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 39: US: Infliximab: Brand & Biosimilar Market Overview
Table 6 40: US: Infliximab (Remicade) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 41: US: Infliximab (Remicade) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 42: US: Adalimumab: Brand & Biosimilar Market Overview
Table 6 43: US: Adalimumab (Humira) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 44: US: Adalimumab (Humira) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 45: US: Ranibizumab: Brand & Biosimilar Market Overview
Table 6 46: US: Ranibizumab (Lucentis) Market: Brand Sales (in Million US$), 2007-2010
Table 6 47: US: Ranibizumab (Lucentis) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 48: US: Omalizumab: Brand & Biosimilar Market Overview
Table 6 49: US: Omalizumab (Xolair) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 50: US: Omalizumab (Xolair) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 51: US: Natalizumab: Brand & Biosimilar Market Overview
Table 6 52: US: Natalizumab (Tysabri) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 53: US: Natalizumab (Tysabri) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 54: US: Bevacizumab: Brand & Biosimilar Market Overview
Table 6 55: US: Bevacizumab (Avastin) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 56: US: Bevacizumab (Avastin) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 57: US: Trastuzumab: Brand & Biosimilar Market Overview
Table 6 58: US: Trastuzumab (Herceptin) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 59: US: Trastuzumab (Herceptin) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 60: US: Rituximab: Brand & Biosimilar Market Overview
Table 6 61: US: Rituximab (Mabthera) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 62: US: Rituximab (Mabthera) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 6 63: US: Cetuximab: Brand & Biosimilar Market Overview
Table 6 64: US: Cetuximab (Erbitux) Market: Brand Sales (in Millions US$), 2007-2010
Table 6 65: US: Cetuximab (Erbitux) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
Table 7 1: US: Biosimilars Market: Indications Assigned for Various Molecules
Table 7 2: US: Biosimilars Market: Sales by Indication (in Million US$), 2007-2010
Table 7 3: US: Biosimilar Market Forecast: Sales by Indication (in Million US$), 2011-2020
Table 7 4: US: Immunology & Inflammation Market: Brand Sales (in Million US$), 2007-2010
Table 7 5: US: Immunology & Inflammation Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020
Table 7 6: US: Immunology & Inflammation Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US$), 2011-2020
Table 7 7: US: Diabetes Market: Brand Sales (in Million US$), 2007-2010
Table 7 8: US: Diabetes Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020
Table 7 9: US: Diabetes Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US$), 2011-2020
Table 7 10: US: Oncology Market: Brand Sales (in Million US$), 2007-2010
Table 7 11: US: Oncology Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020
Table 7 12: US: Oncology Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US$), 2011-2020
Table 7 13 : US: Blood Disorder Market: Brand Sales (in Million US$), 2007-2010
Table 7 14 : US: Blood Disorder Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020
Table 7 15 : US: Blood Disorder Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US$), 2011-2020
Table 7 16 : US: Growth Deficiency Market: Brand & Biosimilar Sales (in Million US$), 2007-2010
Table 7 17 : US: Growth Deficiency Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020
Table 8 1: US: Innovator Companies Facing the Highest Amount of Biosimilar Sales Erosion (in Million US$), 2010, 2013, 2016 & 2020
Table 8 2: Companies Developing Herceptin (Trastuzumab) Biosimilars
Table 8 3: Companies Developing Enbrel (Etanercept) Biosimilars
Table 8 4: Companies Developing Remicade (Infliximab) Biosimilars
Table 8 5: Companies Developing Mabthera (Rituximab) Biosimilars
Table 8 6: Companies Developing Humira (Trastuzumab) Biosimilars
Table 8 7: Companies Developing Other Biosimilars
Table 9 1: US: Overview of Biosimilar Legislations
Table 9 2: Comparison of Patent Protection and Data Exclusivity
